Trial Profile

A PHASE 1 TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PK, AND PD of AX-0810 IN HEALTHY PARTICIPANTS

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 20 Jan 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AX 0810 (Primary)
Indications Liver disorders
Focus Adverse reactions; First in man; Pharmacokinetics
Acronyms PQ-0810-001
Sponsors ProQR Therapeutics

Most Recent Events

08 Jan 2026 Results presented the Media Release ProQR Therapeutics media release.
08 Jan 2026 Status changed from not yet recruiting to recruiting.
08 Jan 2026 According to a ProQR Therapeutics media release, the company announced Phase 1 enrollment and dosing in healthy volunteers ongoing with target engagement data expected in H1 2026, followed by inclusion of a patient cohort.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com